It seems to have taken ages, but the FDA has finally given approval for the Parsortix liquid biopsy test developed by ANGLE (LON: AGL). The share price jumped 58% in the afternoon to 156p, which is the highest it has been since 2005, when it was a different business with a portfolio of investee companies.
The approval covers use with metastatic breast cancer patients. Parsortix is the first system that harvests circulating cancer cells from a blood sample for analysis that has been approved.
This enables biopsies to be done with blood rather than through invasive operations. It is also ...
